scholarly journals A Case of Valproic-Acid Induced Hyperammonemic Encephalopathy

Cureus ◽  
2021 ◽  
Author(s):  
Kinza Iqbal ◽  
Hardhik Kummamuru ◽  
Naresh Dasari ◽  
Thoyaja Koritala ◽  
Nitesh K Jain ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Hyperammonemic Encephalopathy

Valproic Acid-Induced Hyperammonemic Encephalopathy

2002 ◽  
Vol 18 (2) ◽  
pp. 70-74
Author(s):  
Armand Krikorian ◽  
Ala I Sharara ◽  
Riad R Khalifeh
Keyword(s):  
Valproic Acid ◽  
Hyperammonemic Encephalopathy

2764 – Valproic acid induced hyperammonemic encephalopathy: report of one case

2013 ◽  
Vol 28 ◽  
pp. 1 ◽  
Author(s):  
B.B. Annagur ◽  
A.A. Sayin ◽  
N. Akbaba ◽  
Y. Selvi
Keyword(s):  
Valproic Acid ◽  
Hyperammonemic Encephalopathy

Rhabdomyolysis and Hepatotoxicity From Valproic Acid: Case Reports

2019 ◽  
pp. 089719001988288 ◽  
Author(s):  
Cucnhat P. Walker ◽  
Subrata Deb
Keyword(s):  
Valproic Acid ◽  
Acute Kidney Injury ◽  
Case Reports ◽  
Alternative Therapy ◽  
Kidney Injury ◽  
African American Female ◽  
Coagulation Disorders ◽  
Hyperammonemic Encephalopathy ◽  
History Of ◽  
Hispanic Male

Valproic acid (VPA) has been widely used more frequently as its approved indications have been expanded. More and more case reports on rare toxicities have been published in the literature (ie, hepatotoxicities, hyperammonemic encephalopathy, coagulation disorders, pancreatitis, thrombocytopenia). In spite of the long history of VPA, there is a lack of awareness of VPA toxicities among clinicians. We present two cases of a 44-year-old African American female and a 60-year-old Hispanic male taking chronic VPA therapy for psychiatric disorders admitted to the hospital with a combination of hepatotoxicities and acute kidney injury–associated rhabdomyolysis. In both cases, home VPA therapy was continued during hospitalization. Consequently, the female patient deceased and the male patient survived and discharged with continuation of his chronic VPA therapy. In cases of surviving patients, resumption of maintenance VPA upon discharge should be held and alternative therapy should be considered.

Levocarnitine for the Treatment of Valproic Acid–Induced Hyperammonemic Encephalopathy in Children

2019 ◽  
Vol 26 (3) ◽  
pp. e344-e349 ◽  
Author(s):  
Miguel Glatstein ◽  
Pedro Bonifacio Rino ◽  
Silvina de Pinho ◽  
Dennis Scolnik ◽  
Dikla Pivko-Levi ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Hyperammonemic Encephalopathy

scholarly journals Valproic acid induced hyperammonemic encephalopathy: A case report (Turkish)

2018 ◽  
Vol 21 (1) ◽  
pp. 102-106
Author(s):  
Ferda Apa ◽  
Figen Çulha Ateşci ◽  
Gülfizar Sözeri Varma
Keyword(s):  
Valproic Acid ◽  
Case Report ◽  
Hyperammonemic Encephalopathy

scholarly journals Acute Hypoxic Respiratory Failure /Hyperammonemic encephalopathy in the setting of concurrent use of valproic acid and topiramate

2021 ◽  
Vol 9 (4) ◽  
Author(s):  
Fuad Zeid ◽  
Yonas Raru
Keyword(s):  
Valproic Acid ◽  
Respiratory Failure ◽  
Psychiatric Symptoms ◽  
Early Recognition ◽  
Mood Stabilizer ◽  
Metabolic Encephalopathy ◽  
Hyperammonemic Encephalopathy ◽  
Concurrent Use ◽  
Hypoxic Respiratory Failure ◽  
High Index Of Suspicion

Valproic acid (VPA) is widely used for the treatment of epilepsy, migraine, and a variety of psychiatric symptoms, including bipolar disorder, borderline personality disorder, and alcohol withdrawal. Valproate is associated with severe idiosyncratic adverse effects, the most notable being valproate-induced hyperammonemic encephalopathy (VHE). Topiramate is also a broad-spectrum anticonvulsant that is also extensively used for migraine prophylaxis, as a mood stabilizer, and for alcohol dependency. There is increased occurrence of VHE when valproate is used with other medications like phenytoin, phenobarbital, and topiramate. We report a young patient who was on valproic acid and topiramate and developed metabolic encephalopathy with hypoxic respiratory failure with review of the causes and management of the hyperammonemic encephalopathy. We believe that clinicians should be aware of possible hyperammonemic encephalopathy in any patient who is taking valproic acid and presenting with impaired consciousness and cognitive decline. We also underline the importance of early recognition and high index of suspicion of encephalopathy related to hyperammonemia.

Valproic acid and zonisamide induced hyperammonemic encephalopathy

2020 ◽  
Vol 196 ◽  
pp. 105894 ◽  
Author(s):  
Hristelina S. Ilieva ◽  
Joseph W. Newman ◽  
Ronald K. Fields ◽  
John E. Croom
Keyword(s):  
Valproic Acid ◽  
Hyperammonemic Encephalopathy

scholarly journals Two Siblings With Valproate-Related Hyperammonemia and Novel Mutations in Glutamine Synthetase (GLUL) Treated With Carglumic Acid

2020 ◽  
Vol 7 ◽  
pp. 2329048X2096788 ◽  
Author(s):  
Jennifer Bennett ◽  
Christy Gilkes ◽  
Karin Klassen ◽  
Marina Kerr ◽  
Aneal Khan
Keyword(s):  
Valproic Acid ◽  
Case Report ◽  
Glutamine Synthetase ◽  
Negative Correlation ◽  
Seizure Control ◽  
Novel Mutations ◽  
Strong Negative Correlation ◽  
Acid Therapy ◽  
Plasma Ammonia ◽  
Hyperammonemic Encephalopathy

This case report describes 2 siblings with myoclonic epilepsy who had novel mutations in the glutamine synthetase ( GLUL) gene: c.316C>T, p.(Arg106*) and c.42G>C, p.(Lys14Asn). Valproic acid improved seizure control, but was associated with hyperammonemic encephalopathy. Addition of carglumic acid reduced ammonia levels but drug coverage was declined. We therefore designed a protocol to measure the reduction in plasma ammonia in response to carglumic acid therapy. After the first dose of carglumic acid, Patient 1 showed a reduction in plasma ammonia levels within 3 hours, from 114 umol/L to 68 umol/L (reference 12-47 umol/L), and Patient 2 from 108 umol/L to 80 umol/L, which was sustained over a 2 week period. Overall, there was a strong negative correlation between plasma ammonia levels and carglumic acid levels (r = −0.86, p = 0.0013), and recurrence of hyperammonemic encephalopathy was not observed while the patients were taking carglumic acid.

scholarly journals VALPROIC ACID TOXICITY INDUCED BY LACOSAMIDE: A RARE CASE REPORT

2017 ◽  
Vol 10 (9) ◽  
pp. 1 ◽  
Author(s):  
Karthika Ashok Kumar ◽  
Chanshi Chandran ◽  
Remya Reghu
Keyword(s):  
Valproic Acid ◽  
Case Report ◽  
Rare Case ◽  
Hyperammonemic Encephalopathy ◽  
Rare Case Report ◽  
Acid Toxicity

Valproic acid is commonly used in the treatment of both focal and generalized epilepsies and is often tolerated well.Valproic acid is usually tolerated well, but serious complications, including hepatotoxicity and hyperammonemic encephalopathy, may occur. Here we report a case of valproic acid induced hyperammonemic encephalopathy on concomitant use with lacosamide. 

Sign in / Sign up

Export Citation Format

Share Document